Updated overall survival outcomes in ENZAMET (ANZUP 1304)
Prof. Ian Davis elaborates on the ENZAMET trial, the design and updated results of this trial, as well as the overall survival benefit in mHSPC with the addition of enzalutamide.
▶︎
ASCO 2019 ENZAMET (ANZUP 1304) Trial results Plenary presentation
▶︎
Variation in recurrence rate and overall survival outcomes in localised RCC
▶︎
Comparing Apalutamide and Enzalutamide in Real-World Treatment of mCSPC
▶︎
Final analysis of the ATLANTIS cabozantinib comparison
▶︎
She’s 12. She Sings Aretha Franklin… Until Simon TELLS Her to Do It Acapella! 😳
▶︎
This Is Feeding Cancer Cells! How To Cut Off Cancer's Favorite Fuel | Dr. William Li
▶︎
Tomasz Beer, MD Speaks On Xtandi, Erleada, & Nubeqa | Excerpt from the 2019 PCRI Conference
▶︎
FENBENDAZOLE & ARTEMISININ I The Common Sense MD I Dr. Tom Rogers
▶︎
16 Years: Surviving Metastatic #ProstateCancer | Joel Nowak, CEO of @Cancer ABCs | #PCRI
▶︎
Ask This ONE Question Before You Trust Them (Liars & Cheaters Reveal Themselves Fast) | Chase Hughes
▶︎
Management of Advanced Hormone-sensitive and Castration-resistant Prostate Cancer
▶︎
Nervous System Regulation (999 Hz) | 1 hour handpan music | Malte Marten
▶︎
Ages 75–85: If You Still Do These 6 Things, You’re Truly One Of A Kind | Dr David Sinclair
▶︎
Xtandi Patient Stories
▶︎
#ProstateCancer: Cure vs Remission After Treatment | #markscholzmd | #pcri
▶︎
"This Food Can Repair DNA & Starve Cancer!" - What You NEED TO KNOW!
▶︎
TITAN Phase 3 Trial with Apalutamide in Metastatic Castration Sensitive Prostate Cancer
▶︎
Over 60? Drink THIS to BOOST Blood Flow in Legs Fast || Dr. Alan Mandell
▶︎
Managing an Elevated PSA: Avoiding Unnecessary Prostate Biopsies
▶︎